Toth Financial Advisory Corp Sells 29 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Toth Financial Advisory Corp trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.5% during the first quarter, Holdings Channel reports. The institutional investor owned 120 shares of the medical equipment provider’s stock after selling 29 shares during the quarter. Toth Financial Advisory Corp’s holdings in Intuitive Surgical were worth $48,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in ISRG. Vanguard Group Inc. raised its holdings in shares of Intuitive Surgical by 0.7% in the third quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after purchasing an additional 196,316 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Intuitive Surgical by 1.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,973,266 shares of the medical equipment provider’s stock valued at $5,726,102,000 after purchasing an additional 272,741 shares during the last quarter. Edgewood Management LLC raised its holdings in shares of Intuitive Surgical by 7.9% in the fourth quarter. Edgewood Management LLC now owns 5,131,066 shares of the medical equipment provider’s stock valued at $1,731,016,000 after purchasing an additional 374,667 shares during the last quarter. Fisher Asset Management LLC increased its holdings in Intuitive Surgical by 2.0% during the fourth quarter. Fisher Asset Management LLC now owns 4,494,373 shares of the medical equipment provider’s stock worth $1,516,222,000 after buying an additional 88,977 shares during the last quarter. Finally, Norges Bank purchased a new stake in Intuitive Surgical during the fourth quarter worth about $1,313,238,000. 83.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

ISRG has been the subject of a number of analyst reports. Citigroup raised their price objective on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. BTIG Research raised their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research report on Friday, April 19th. Jefferies Financial Group lifted their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a research report on Friday, April 19th. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating for the company in a research report on Friday, April 19th. Finally, Piper Sandler lifted their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research report on Friday, April 19th. Five research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $403.67.

Insider Buying and Selling at Intuitive Surgical

In other news, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other news, Director Craig H. Barratt sold 1,400 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Alan J. Levy sold 2,000 shares of the business’s stock in a transaction on Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total transaction of $741,400.00. Following the sale, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,956 shares of company stock valued at $6,927,011. 0.90% of the stock is currently owned by company insiders.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded down $0.26 during mid-day trading on Friday, hitting $444.85. The stock had a trading volume of 3,106,192 shares, compared to its average volume of 1,372,778. Intuitive Surgical, Inc. has a 1 year low of $254.85 and a 1 year high of $447.11. The business has a 50 day moving average price of $403.83 and a two-hundred day moving average price of $382.69. The firm has a market cap of $157.79 billion, a P/E ratio of 80.30, a price-to-earnings-growth ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.00 EPS. Equities research analysts predict that Intuitive Surgical, Inc. will post 4.8 EPS for the current fiscal year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.